Bioequivalence Study of Aripiprazole 3 mg Orally Disintegrating Tablet and 3 mg Conventional Tablet in Healthy Adult Male Subjects

  Aripiprazole orally disintegrating tablet is a new formulation that was developed for easier swallowing by schizophrenia patients with dysphagia and for use in patients in whom treatment using a conventional tablet or powder formulation is difficult or adherence is unreliable, such as patients who tend to refuse drug therapy because they cannot understand the necessity of taking the drug due to their clinical state.
  The two trials were conducted using a randomized, two-treatment, two-period, open-label crossover method to verify the bioequivalence of 3-mg of aripiprazole orally disintegrating tablets to 3-mg of aripiprazole conventional tablets, under fasting conditions, in 44 healthy adult male subjects. One trial was the without-water trial which the orally disintegrating tablets was administered without water in. Another trial was the with-water trial which the orally disintegrating tablets was administered with water in. A washout period of 35 days was set between study drug administration in Periods I and II.
  In the without-water trial, the 90% CI(confidence intervals)for the differences in the mean log-transformed AUC168h and Cmax values between the orally disintegrating tablet without water and the conventional tablet were log(0.96)to log(1.04)and log(0.97)to log(1.07)respectively. In the with-water trial, the 90% CI for the differences in the mean log-transformed AUC168h and Cmax values between the orally disintegrating tablet with water and the conventional tablet were log(0.92)to log(1.04)and log(0.88)to log(1.02)respectively. As both 90% CI in both trials were within the bioequivalence criteria range of log(0.8)to log(1.25), it was judged that the two formulations were bioequivalent.
  All of the adverse drug reactions observed in this study have been previously reported as adverse drug reactions for aripiprazole in prior oral aripiprazole studies conducted in Japan, and aripiprazole orally disintegrating tablet is therefore considered to pose no particular safety problems. No deaths or serious adverse events occurred.